Research Canada

#Budget2024: Research Canada welcomes the Government of Canada's renewed commitment to health research, innovation and talent. New investments include: ✅ $1.8 billion to CIHR, NSERC and SSHRC ✅ $825 million to raise federal scholarships and fellowships ✅ $600 million for major research and science infrastructure investments ✅ $30 million to support Indigenous researchers and their communities Read our response: https://ow.ly/7Msn50RhHeY

Happy Holidays and Happy New Year from Research Canada! As we wrap up 2024, we want to take a moment to thank all of our incredible members, partners, and supporters for another amazing year of collaboration and progress in health research and innovation. We’re excited for what 2025 will bring and can’t wait to continue working together to drive innovation and change. Wishing you all a joyful holiday season and a bright, healthy New Year ahead!

I am so proud of our final Parliamentary Health Research Caucus event of 2024, presented in partnership with the Canadian Cancer Society last Thursday.    Our panelists were stellar: many thanks to Suzanne Wood, a patient advocate who shared her cancer journey with us with candour and grace; and to Dr.Rebecca Auer of the Ottawa Hospital Research Institute and Dr. Janet Dancey of the Canadian Cancer Trials Group and Queen's University—both champions of clinical research, and the need help more people understand and access clinical trials as a form of care.   A great feature of working with the Canadian Cancer Society was we got to draw together many Parliamentarians from all parties who regularly support our respective and collective work. Thanks to all who chose to spend their time with us! A highlight was the luncheon in the Adam Room of the festive Fairmont Château Laurier, where guests, experts and sponsors networked, shared stories, and met one-on-one with our panelists and the experts who took part in our Innovation Showcase including: Jennifer Brooks of CanPath - Canadian Partnership for Tomorrow's Health; Seidah Nabil of Institut de recherches cliniques de Montréal (IRCM) / Montreal Clinical Research Institute; Desmond Pink of Nanostics Inc.; John Bell of BioCanRx & The Terry Fox Research Institute; Jeanette Boudreau of the Beatrice Hunter Cancer Research Institute; Stephen Sundquist of the Canadian Cancer Clinical Trials Network; and 🇨🇦Irsa Wiginton, of mDETECT Inc and Queen's University.   ‘Twas a great way to round out 2024 programming. See you in 2025, as Research Canada continues to showcase the health breakthroughs and innovative treatments that will change our health and economy for the better. Stuart E., Tarik Moroy, Ph.D., FCAHS, Bill Dempster, Cynthia Di Lullo, Isabelle Gagnon, Shona Kinley, Francois Laflamme, Stephanie Michaud, Cate Murray, Sophie Normand, Viviane Poupon #ResearchIsCare #HealthResearch #CancerCare #HealthInnovation #Cancer #ClinicalResearch

Last week, IMC’s Director of Federal Government Affairs, Sophie Normand, spoke at the Parliamentary Health Research Caucus Morning Panel and Innovation Showcase Luncheon on Disruptive Innovation in Cancer Research. Hosted by Research Canada and the Canadian Cancer Society, this event brought together policymakers, researchers, patient advocates, and industry leaders to discuss advancements in cancer care and clinical trials. In her remarks, Normand highlighted IMC’s commitment to improving access to effective treatments, advancing personalized medicine, and supporting better healthcare outcomes for Canadians. With one in two Canadians expected to face a cancer diagnosis in their lifetime, there is an urgent need for innovative solutions to address this challenge. IMC will continue working with stakeholders to support progress in cancer care. Together, we can make a difference—not just in survival rates, but in the quality of life for patients and families across the country. IMC is proud to stand alongside leaders in cancer research and care to build a healthier future for all Canadians. #CancerAwareness #HealthcareInnovation #PatientCenteredCare // La semaine dernière, Sophie Normand, directrice des Affaires gouvernementales fédérales de Médicaments novateurs Canada (MNC), s’est exprimée lors de la discussion matinale et du déjeuner du Comité parlementaire sur la recherche en santé, qui portait sur le thème de l’innovation perturbatrice dans la recherche sur le cancer. Organisé par Research Canada et la Canadian Cancer Society, cet événement a réuni des responsables des politiques, des chercheurs, des défenseurs des patients et des chefs de file de l’industrie pour discuter des progrès réalisés dans le domaine des soins aux personnes atteintes de cancer et des essais cliniques en cancérologie. Dans ses allocutions, Sophie Normand a souligné la détermination de MNC à améliorer l’accès à des traitements efficaces, à faire progresser la médecine personnalisée et à favoriser l’amélioration des résultats sur la santé pour la population canadienne. Alors qu’un Canadien sur deux risque de recevoir un diagnostic de cancer au cours de sa vie, il est urgent de trouver des solutions novatrices pour faire face à ce défi. MNC continuera à travailler avec les parties prenantes pour soutenir les progrès dans les soins aux personnes atteintes de cancer. Ensemble, nous pouvons améliorer la situation, non seulement le taux de survie, mais aussi la qualité de vie pour les patients et leurs familles partout au pays. MNC est fière d’être aux côtés des chefs de file de la recherche sur le cancer et des soins aux personnes qui en sont atteintes pour construire un avenir plus sain pour tous les Canadiens. #SensibilisationAuCancer #InnovationEnSoinsDeSanté #SoinsCentrésSurLesPatients

Reflecting on last week’s Parliamentary Health Research Caucus Event on Disruptive Innovation in Cancer Research, co-hosted by the Canadian Cancer Society. It was an incredible opportunity to bring together so many passionate experts—policymakers, researchers, clinicians, and industry leaders—all focused on advancing cancer research and care in Canada. A big thank you to the inspiring speakers and generous sponsors for making this event a success. The conversations were thought-provoking, and we are excited about the progress we can continue to make together in shaping the future of cancer care. #CancerResearch #Innovation #Healthcare #DisruptiveInnovation #Collaboration

A big thank you to everyone who participated in yesterday’s Parliamentary Health Research Caucus Event on Disruptive Innovation in Cancer Research, co-hosted by the Canadian Cancer Society! 🧬✨ We’re grateful to have brought together policymakers, researchers, clinicians, and industry leaders to discuss how disruptive innovations are driving the future of cancer research and care in Canada. The insights shared yesterday are essential to advancing our collective efforts in improving cancer outcomes and transforming healthcare. A special thank you to our exceptional speakers, whose expertise sparked thought-provoking conversations, and to our generous sponsors for their support in making this event a success. Pfizer, AstraZeneca, BioCanRx, Ottawa Hospital Research Institute, Ovarian Cancer Canada, Innovative Medicines Canada - Médicaments novateurs Canada, CanPath - Canadian Partnership for Tomorrow's Health, Nanostics Inc., Merck Canada, Novartis, Queen's University and BD-Canada. Also, thank you to The The Terry Fox Research Institute on supporting the event.

Pfizer was proud to partner and participate in Research Canada's Parliamentary Health Research Caucus Event and Innovation Showcase on Disruptive Innovation in Cancer Research in Ottawa yesterday. This event featured some of the best and brightest Canadian health researchers. The future of cancer care in Canada is poised to undergo a remarkable transformation, driven by a surge of scientific advances and a renewed commitment to ensuring equitable access for all patients. Pfizer is actively engaged working together with healthcare providers, payers and patient groups to design solutions that meet the needs of the patient. At Pfizer, we believe that time is life. And for people living with cancer, each day matters. Thank you to Research Canada for shining a light on the amazing work being done by Canadian researchers in this critical area of healthcare. Read more about Pfizer’s commitment to advancing cancer care in Canada through collaborative innovation: https://lnkd.in/eUaDtKTG

🚨 Tomorrow! 🚨 We’re thrilled to host the Parliamentary Health Research Caucus Event on Disruptive Innovation in Cancer Research, co-hosted by the Canadian Cancer society, tomorrow, December 12! 🧬✨ This event brings together policymakers, researchers, clinicians, and industry leaders to discuss the latest breakthroughs in cancer research and how disruptive innovation is transforming the future of cancer care in Canada. Our amazing speakers include: - Dr. Stuart E., EVP, Canadian Cancer Society - Dr. Rebecca Auer, CEO & Scientific Director, Ottawa Hospital Research Institute - Dr. Janet Dancey, Director, Canadian Cancer Trials Group Suzanne Wood, Patient Advocate - Dr. Jennifer Brooks, Executive Director, CanPath - Canadian Partnership for Tomorrow's Health - Dr. Seidah Nabil, Director, Institut de recherches cliniques de Montréal (IRCM) / Montreal Clinical Research Institute - Dr. Desmond Pink, Co-founder, Nanostics Inc., University of Alberta - Dr. John Bell, BioCanRx & The Terry Fox Research Institute - Dr. Jeanette Boudreau, Scientific Director, Beatrice Hunter Cancer Research Institute - Dr. Stephen Sundquist, Executive Director, Canadian Cancer Clinical Trials Network - Dr. 🇨🇦Irsa Wiginton Wiginton, Co-Founder & Chief Development Officer, mDETECT Inc & Queen's University We are excited to be part of a conversation that’s driving meaningful change in healthcare. Together, we can help shape the future of cancer research and care in Canada. A big thank you to our sponsors, Pfizer, AstraZeneca, BioCanRx, Ottawa Hospital Research Institute, Ovarian Cancer Canada, Innovative Medicines Canada - Médicaments novateurs Canada, CanPath - Canadian Partnership for Tomorrow's Health, Nanostics Inc., Merck Canada, Novartis, Queen's University and BD-Canada, for your support in making the day a big success. Also, thank you to The Terry Fox Research Institute on supporting the event. Stay tuned for updates throughout the day!

🚨 THIS WEEK! 🚨 We’re thrilled to announce our upcoming event, "Disruptive Innovation in Cancer Research," hosted the Parliamentary Health Research Caucus, and co-hosted by the Canadian Cancer Society. Website 👉 https://lnkd.in/edCVr7Ui This event will dive into the transformative power of disruptive innovations in cancer care and research, with a special focus on how clinical trials are accelerating life-saving breakthroughs. We’ll explore how these trials are not only advancing cutting-edge treatments but also improving patient outcomes and reshaping the future of cancer care in Canada. A heartfelt thank you to our incredible sponsors who are making this event possible: Pfizer AstraZeneca BioCanRx Ovarian Cancer Canada BD-Canada Ottawa Hospital Research Institute Innovative Medicines Canada - Médicaments novateurs Canada Nanostics Inc. CanPath - Canadian Partnership for Tomorrow's Health Merck Canada Novartis Canada Queen's University And a special thanks to our supporter: The Terry Fox Research Institute. We are grateful for your ongoing support in advancing cancer research, expanding access to clinical trials, and driving innovation in cancer care. Together, we can make a lasting impact on the fight against cancer.

We’re thrilled to announce the Cancer Caucus and Parliamentary Health Research Caucus Event on Disruptive Innovation in Cancer Research! On December 12, in partnership with the Canadian Cancer Society, we’re bringing together top experts to explore how disruptive innovations are transforming cancer research and treatment in Canada. This event offers a unique opportunity to hear from researchers, healthcare leaders, and policymakers about the groundbreaking advancements shaping the future of cancer care. Event page 👉 https://lnkd.in/edCVr7Ui #CancerResearch #Innovation #HealthPolicy #DisruptiveInnovation #ResearchCanada #CanadianCancerSociety